Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms

NACompletedINTERVENTIONAL
Enrollment

12,000

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

July 12, 2021

Study Completion Date

July 12, 2021

Conditions
Opioid Use
Interventions
BEHAVIORAL

PMP Use Mandate Letter

A letter with reminders about the mandate to check the PMP when prescribing opioids.

BEHAVIORAL

Prescribing Information Letter

A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.

BEHAVIORAL

Prescribing Information + PMP Use Mandate Letter

A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.

Trial Locations (2)

55155

Minnesota Management and Budget Agency, Saint Paul

55414

Minnesota Board of Pharmacy, Minneapolis

All Listed Sponsors
collaborator

University of Southern California

OTHER

collaborator

Minnesota Management and Budget Agency

UNKNOWN

collaborator

Minnesota Board of Pharmacy

OTHER

lead

Columbia University

OTHER